StockData
MannKind Corp logo

MannKind Corp (MNKD) stock

MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30273% above fair value
$4.13−0.03 (-0.72%)

Close on Nov 13, 2026Market cap $1.33BP/E –Yield –

MannKind r&d expenses

Research and development expenses are spending on new products and technology.

MannKind's R&D Expenses for the twelve months ending Sep 30, 2026 was $77.18M, up 54.7% year over year. For fiscal 2025 it was $66.35M, up 44.6% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $156.33M in fiscal 2009.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.35M+44.6%
FY2024Dec 31, 2024$45.89M+46.7%
FY2023Dec 31, 2023$31.28M+58.6%
FY2022Dec 31, 2022$19.72M+60.2%
FY2021Dec 31, 2021$12.31M+97.1%
FY2020Dec 31, 2020$6.25M-9.4%
FY2019Dec 31, 2019$6.90M-21.0%
FY2018Dec 31, 2018$8.74M-38.1%
FY2017Dec 31, 2017$14.12M-5.4%
FY2016Dec 31, 2016$14.92M-49.7%
FY2015Dec 31, 2015$29.67M-70.4%
FY2014Dec 31, 2014$100.24M-8.6%
FY2013Dec 31, 2013$109.72M+8.1%
FY2012Dec 31, 2012$101.52M+1.6%
FY2011Dec 31, 2011$99.96M-11.0%
FY2010Dec 31, 2010$112.28M-28.2%
FY2009Dec 31, 2009$156.33M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$14.36M+2.1%
Q2 FY2026Jun 30, 2026$18.00M+31.6%
Q1 FY2026Mar 31, 2026$17.23M+56.3%
Q4 FY2025Dec 31, 2025$27.59M+147.7%
Q3 FY2025Sep 30, 2025$14.06M+8.8%
Q2 FY2025Jun 30, 2025$13.68M+15.7%
Q1 FY2025Mar 31, 2025$11.02M+10.1%
Q4 FY2024Dec 31, 2024$11.14M+20.6%
Q3 FY2024Sep 30, 2024$12.93M+29.4%
Q2 FY2024Jun 30, 2024$11.82M+83.1%
Q1 FY2024Mar 31, 2024$10.01M+78.6%
Q4 FY2023Dec 31, 2023$9.24M+29.1%
Q3 FY2023Sep 30, 2023$9.99M+141.5%
Q2 FY2023Jun 30, 2023$6.45M+31.9%
Q1 FY2023Mar 31, 2023$5.61M+58.5%
Q4 FY2022Dec 31, 2022$7.16M+84.1%
Q3 FY2022Sep 30, 2022$4.14M+13.2%
Q2 FY2022Jun 30, 2022$4.89M+110.1%
Q1 FY2022Mar 31, 2022$3.54M+44.8%
Q4 FY2021Dec 31, 2021$3.89M+151.5%
Q3 FY2021Sep 30, 2021$3.66M+146.3%
Q2 FY2021Jun 30, 2021$2.33M+59.1%
Q1 FY2021Mar 31, 2021$2.44M+39.1%
Q4 FY2020Dec 31, 2020$1.55M-23.6%
Q3 FY2020Sep 30, 2020$1.48M-6.1%
Q2 FY2020Jun 30, 2020$1.46M-10.3%
Q1 FY2020Mar 31, 2020$1.76M+5.3%
Q4 FY2019Dec 31, 2019$2.02M+86.4%
Q3 FY2019Sep 30, 2019$1.58M-22.7%
Q2 FY2019Jun 30, 2019$1.63M-45.0%
Q1 FY2019Mar 31, 2019$1.67M-37.0%
Q4 FY2018Dec 31, 2018$1.08M-69.1%
Q3 FY2018Sep 30, 2018$2.04M-53.2%
Q2 FY2018Jun 30, 2018$2.97M-5.0%
Q1 FY2018Mar 31, 2018$2.64M-15.5%
Q4 FY2017Dec 31, 2017$3.51M+124.8%
Q3 FY2017Sep 30, 2017$4.36M–
Q2 FY2017Jun 30, 2017$3.12M–
Q1 FY2017Mar 31, 2017$3.13M–
Q4 FY2016Dec 31, 2016$1.56M–

More MannKind figures

See a number that looks wrong?